Medical methods to terminate early pregnancy (Q37976773)

26 August 2017

1 reference

title

Medical methods to terminate early pregnancy (English)

1 reference

26 August 2017

M L Swahn

1 reference

26 August 2017

M Bygdeman

series ordinal

1 reference

26 August 2017

publication date

1 June 1990

1 reference

Bailliere's clinical obstetrics and gynaecology

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

293-306

1 reference

Effects of Epostane on progesterone synthesis in early human pregnancy

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early human pregnancy with epostane

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Anti-progesterones for the interruption of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early pregnancy. Future development

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl-trans-Delta;2-PGE, methyl ester) or the antiprogestogen RU 486

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (gemeprost)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

The prospects of PGs in postconceptional therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

The efficacy and acceptability of the ″prostaglandin impact″ in inducing complete abortion during the second week after the missed menstrual period

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Menstrual induction in preference to abortion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Contragestion with late luteal administration of RU 486 (Mifepristone)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Studies on the mechanisms of action of progesterone antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Early pregnancy-abortion model using sulprostone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Transplacental passage of mifepristone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

15(S)15-Methyl protaglandin F2α for termination of very early human pregnancy. A comparative study of a single intramuscular injection and vaginal suppositories

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Interruption of early first trimester pregnancy by single vaginal administration of 15-methyl-pgf2 alpha-methyl ester

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Development of a vaginal gel containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 for cervical dilatation and pregnancy termination

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Early abortion by vaginal prostaglandin suppositories. Blood loss in relation to elimination of serum chorionic gonadotrophin, progesterone and estradiol-17 beta

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

A luteolytic effect of a prostaglandin F2 alpha analogue in non-pregnant women?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Interruption of early pregnancy by an anti-progestational compound, RU 486

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Menstrual induction with vaginal administration of 16,16 dimethyl trans-Δ2-PGE methyl ester (ONO 802)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

The stimulation of prostaglandin production by two antiprogesterone steroids in human endometrial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Treatment with a single vaginal suppository containing 15-methyl PGF2α methyl ester at expected time of menstruation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of very early pregnancy by RU 486--an antiprogestational compound

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Late postcoital treatment against pregnancy with antiprogesterone RU 486

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Uteroglobin inhibits phospholipase A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Very early abortion by prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

1 reference

7 January 2021

Inhibition of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in first- and second-trimester human pregnancy and the luteal phase using Epostane

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Induced cervical ripening with Mifepristone in first trimester abortion. A double-blind randomized biomechanical study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Randomized comparison of prostaglandin treatment in hospital or at home with vacuum aspiration for termination of early pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

The effect of the antiprogestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2 alpha and E2 in separated cells from early human decidua

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early pregnancy with RU 486 (mifepristone) in combination with a prostaglandin analogue (sulprostone)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Oral administration of RU 486 and 9-methylene PGE2 for termination of early pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Therapeutic abortion of early human gestation with vaginal suppositories of prostaglandin F2α

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Uses of RU 486 for contragestion: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Myometrial activity in first trimester human pregnancy after Epostane therapy. Effect of intravenous oxytocin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Interruption of first trimester human pregnancy following Epostane therapy. Effect of prostaglandin E2 pessaries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Menstrual regulation by intramuscular injections of 16-phenoxy-tetranor PGE2 methyl sulfonylamide or vacuum aspiration. A randomized multicentre study. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980228-7

7 January 2021

10.1016/S0950-3552(05)80228-7

Identifiers

DOI

1 reference

26 August 2017

1 reference